Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
4.485
+0.135 (3.10%)
At close: Jun 26, 2026, 4:00 PM EDT
4.490
+0.005 (0.11%)
After-hours: Jun 26, 2026, 4:31 PM EDT
Atea Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Atea Pharmaceuticals stock have an average target of 8.00, with a low estimate of 6.00 and a high estimate of 10. The average target predicts an increase of 78.37% from the current stock price of 4.49.
Analyst Consensus: Buy
* Price targets were last updated on May 18, 2026.
Analyst Ratings
The average analyst rating for Atea Pharmaceuticals stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '25 | Nov '25 | Jan '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $6 | Hold | Maintains | $6 | +33.78% | May 18, 2026 |
| William Blair | William Blair | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | May 13, 2026 |
| Evercore ISI | Evercore ISI | Buy Maintains $6 → $10 | Buy | Maintains | $6 → $10 | +122.97% | Mar 9, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
30.17M
EPS This Year
-1.93
from -1.94
EPS Next Year
-1.39
from -1.93
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | 60.3M | |
| Avg | n/a | 30.2M | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | 370.8% |
| Avg | - | 135.4% |
| Low | - | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | -1.93 | -1.39 | |
| Low | - | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.